Social Media Ideas for Aedax

ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achiev...

- - • Data from the head-to-head study show efdoralprin alfa normalized and maintained functional AAT levels in people living with alpha-1 antitrypsin deficiency - • Efdoralpr...

ADA: Tolerability ‘not to be underappreciated’ in Roche, Zealand’s amylin obesity prospect

As the American Diabetes Association 2026 Scientific Sessions kicked off in New Orleans over the weekend, Zealand Pharma and its recent commercial and development partner Roche hel...

Baxfendy approved in the US as the first and only aldosterone synthase inhibitor treatment for adults with hypertension

AstraZeneca's Baxfendy (baxdrostat) has been approved in the US as a first-in-class aldosterone synthase inhibitor (ASI) for the treatment of hypertension in combination with oth...

Applied Aerospace & Defense seeks $3.59 billion valuation in IPO

Levicept appoints Darlene Deptula-Hicks as CFO

Applied Aerospace & Defense: Mission-Critical Defense Content Justifies A Buy

Adeka Corporation 2026 Q4 - Results - Earnings Call Presentation

Argenx

Argenx Anonymous (not verified) Sun, 06/07/2026 - 17:48 field_thread_url https://cafepharma.com/boards/threads/argenx.665212/ board name...

ADA: AZ’s oral GLP-1 shows ‘competitive efficacy’ in phase 2, setting stage for pivotal program

With a pair of phase 2 readouts, AstraZeneca is positioning itself to potentially capture a portion of the oral GLP-1 market. Up next, its elecoglipron is heading into pivotal stud...